nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Clinical pharmacokinetics of TNF antagonists: How do they differ?
|
Nestorov, Ivan |
|
2005 |
|
5S1 |
p. 12-18 7 p. |
artikel |
2 |
Differentiating the efficacy of the tumor necrosis factor inhibitors
|
Haraoui, Boulos |
|
2005 |
|
5S1 |
p. 7-11 5 p. |
artikel |
3 |
Distinct mechanisms of action of tumor necrosis factor antagonists: What are the clinical implications?
|
Rigby, William F.C. |
|
2005 |
|
5S1 |
p. 1-2 2 p. |
artikel |
4 |
Diverse effects of infliximab and etanercept on T lymphocytes
|
Sieper, Joachim |
|
2005 |
|
5S1 |
p. 23-27 5 p. |
artikel |
5 |
Epidemiology of lymphoma development in patients with rheumatoid arthritis
|
Ekbom, Anders |
|
2005 |
|
5S1 |
p. 28-30 3 p. |
artikel |
6 |
Sponsorship page
|
|
|
2005 |
|
5S1 |
p. A2- 1 p. |
artikel |
7 |
Table of contents
|
|
|
2005 |
|
5S1 |
p. A1- 1 p. |
artikel |
8 |
TNF pathophysiology in murine models of chronic inflammation and autoimmunity
|
Kollias, George |
|
2005 |
|
5S1 |
p. 3-6 4 p. |
artikel |
9 |
Tumor necrosis factor and granuloma biology: Explaining the differential infection risk of etanercept and infliximab
|
Wallis, Robert S. |
|
2005 |
|
5S1 |
p. 34-38 5 p. |
artikel |
10 |
Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles
|
Anderson, Paul J. |
|
2005 |
|
5S1 |
p. 19-22 4 p. |
artikel |
11 |
What are the links between Epstein-Barr virus, lymphoma, and tumor necrosis factor antagonism in rheumatoid arthritis?
|
Balandraud, Nathalie |
|
2005 |
|
5S1 |
p. 31-33 3 p. |
artikel |